

Stealth BioTherapeutics Announces Departure of Chief Financial Officer



Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's financial team.

"On behalf of the entire team and Board of Directors, we thank Rob for his significant contributions to Stealth over the past few years, and wish him the best in his future endeavors," said Reenie McCarthy, Stealth's CEO. "Rob has played a key role in building the infrastructure to support Stealth as a public company and developing its accounting and reporting capabilities. Rob leaves the company with a strong accounting and financial reporting foundation as well as a talented finance and accounting team," Ms. McCarthy said. On August 1, 2022, the Company announced that it had entered into a definitive agreement to be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd. for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC in an all-cash going private transaction.

Mr. Weiskopf said, "It has been an honor to serve as CFO of Stealth over the past three years. I have confidence in the Company's finance and management team to guide the Company into its next stage of development. I look forward to seeing the Company continue to progress its strategy to develop novel therapies for patients with high unmet needs due to diseases involving mitochondrial dysfunction."

Source: [Stealth BioTherapeutics Corp](#)

Published on : Fri, 30 Sep 2022